Sublicense Agreement



 Exhibit 10.1 
 SUBLICENSE AGREEMENT 
 BETWEEN 
 REVIMMUNE, LLC 
 AND 
 ACCENTIA BIOPHARMACEUTICALS, INC. 
 This Sublicense
Agreement (this “Agreement or “Sublicense Agreement”) effective as of February 27, 2007, by and between Revimmune, LLC, a Florida limited liability company, (“Revimmune”), and ACCENTIA BIOPHARMACEUTICALS, INC.,
a Florida corporation, (“Accentia”) (collectively the “Parties”). 
 WITNESSETH: 
 Whereas, REVIMMUNE has received an exclusive worldwide license to certain rights arising from pending patent applications, along with associated
know-how, as specifically defined in the License Agreement between Revimmune and Johns Hopkins University (the “JHU License”) which became effective by signature of Johns Hopkins University on February 20, 2006 (the “Revimmune
Licensed Rights”); 
 Whereas, the founders of REVIMMUNE began negotiating with various personnel at JHU for the potential acquisition of the Revimmune
Licensed Rights in 2003; 
 Whereas, the founder of REVIMMUNE obtained a Notice of Allowance for the trade name “REVIMMUNE” on March 25, 2003;

 Whereas, REVIMMUNE was organized as a limited liability company by filing articles of organization with the State of Florida on January 16, 2006;

 Whereas, ACCENTIA recognizes that the REVIMMUNE Licensed Rights are valuable for drug development, use and/or sale in the treatment or prevention of human
diseases; 
 Whereas, ACCENTIA wishes to enter into an agreement to obtain an exclusive sublicense to the Sublicensed Products from REVIMMUNE in order to
develop, promote, market and commercialize prophylactic and/or therapeutic products or treatments for the indications of all autoimmune diseases including but not limited to multiple sclerosis; 
 Whereas, the Revimmune License names ACCENTIA as an affiliate of REVIMMUNE for all purposes under the Revimmune License; and 
 WHEREAS, REVIMMUNE is willing to grant such sublicense to ACCENTIA under the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows: 
  

 1 








 ARTICLE 1 - DEFINITIONS 
 Capitalized terms, not otherwise defined herein shall have the meaning assigned to them in the JHU License. For purposes of this Agreement, the following terms shall have the meanings set forth below: 
  

	1.1	“Effective Date” shall mean the date first written above. 

  

	1.2	“Territory” shall mean worldwide. 

  

	1.3	“Sublicensed Rights” shall mean the Revimmune Licensed Rights plus any intellectual property rights acquired by REVIMMUNE either prior to the date of this Agreement or
hereafter during the term of this Agreement (whether acquired from JHU, another third party, or through internal development activities) reasonably related to Sublicensed Products. 

  

	1.4	“Sublicensed Products” shall mean any materials, compositions, drugs, or other products, methods or services which are in material part first identified, discovered, made,
or commercialized by practicing one or more valid claims included in the patents that are part of the Sublicensed Rights. 

  

	1.5	“Sublicense Indications” shall mean all autoimmune diseases including but not limited to multiple sclerosis. For clarification, organ, bone and other transplants and
cancer are excluded from the definition of Sublicense Indications. 

  

	1.6	“Sublicensed Royalty” shall have the meaning set forth in Article 4 hereof. 

  

	1.7	“Revimmune Licensed Rights” shall mean the rights granted to REVIMMUNE in the JHU License. 

  

	1.8	“JHU License” shall mean the License Agreement between Johns Hopkins University and REVIMMUNE which became effective by signature of Johns Hopkins University on February
20, 2006. 

  

	1.9	“JHU” shall mean John Hopkins University. 

  

	1.10	“Affiliate” shall mean, with respect to a specified person or entity, any other person or entity that controls, is controlled by, or is under common control (whether
through equity ownership, contract, or otherwise) the specified person or entity. 

 ARTICLE 2 - REPRESENTATIONS AND
WARRANTIES; RESPONSIBILITIES OF THE PARTIES 
 2.1 Representations and Warranties of Both Parties. Each Party represents and warrants to the other
Party that: (i) it is free to enter into this Sublicense Agreement; (ii) in so doing, it will not violate any other agreement to which it is a party; and (iii) it has taken all corporate action necessary to authorize the execution and
delivery of this Agreement and the performance of its obligations under this Agreement. 
  

 2 








 2.2 Representations and Warranties of REVIMMUNE. REVIMMUNE hereby represents and warrants that: 
 (a) The JHU License is in full force and effect, and REVIMMUNE has the right to grant the sublicense thereunder without the consent or approval of any
third party; 
 (b) To the best of REVIMMUNE’s knowledge, all the REVIMMUNE Licensed Rights listed in the JHU License are in full force
and effect and have been maintained to date; 
 (c) REVIMMUNE is not aware of any asserted or unasserted claim or demand against the
REVIMMUNE Licensed Rights; 
 (d) None of the REVIMMUNE Licensed Rights infringes upon any patent or other proprietary rights of any third
party; and 
 (e) REVIMMUNE has not entered into any agreement with any other entity which is in conflict with the rights granted to ACCENTIA
pursuant to this Sublicense Agreement. 
 2.3 Representations and Warranties of Accentia. ACCENTIA hereby represents and warrants that: 
 (a) ACCENTIA has the right to enter into this Sublicense Agreement without the consent of any third party; 
 (b) ACCENTIA will exercise reasonable efforts to develop, promote, market, sell and commercialize the Sublicensed Rights for all Sublicense Indications;
and 
 (c) ACCENTIA has no right in or to the JHU License or the Licensed Products except only those rights and interest expressly granted
hereunder. 
 2.4 Employee Agreements. Each Party warrants that it has, and covenants that it will have, entered into a proprietary information
and inventions agreement with each of its employees prior to the time that any such employee shall receive confidential information from a disclosing party under this Agreement or begin work related to this Agreement. Such agreement shall minimally
set forth employee obligations to assign inventions to the inventing Party and to maintain confidentiality of confidential information consistent with the terms of this Agreement. 
 2.5 REVIMMUNE Responsibilities. REVIMMUNE will be responsible to maintain the JHU License in full force and effect. 
 2.6 ACCENTIA Responsibilities.  
  

	 	(a)	ACCENTIA will be responsible, at its sole cost and expense, for the development, promotion, marketing, sales and commercialization of the Sublicensed Rights in connection with each
of the Sublicense Indications. 

  

	 	(b)	ACCENTIA will during the term of this Sublicense Agreement use commercially reasonable efforts to continuously develop, promote, sell, market and commercialize the Sublicensed
Products for each of the Sublicense Indications. 

  

 3 









	 	(c)	Subject to Section 3.3 and Article 6 hereof, ACCENTIA shall share with REVIMMUNE all proprietary and clinical data and information related to the Sublicensed Products,
Sublicensed Rights and any related clinical trial which data and information may be used by REVIMMUNE in support of the development and commercialization of products for indications other than the Sublicense Indications. 

  

	 	(d)	ACCENTIA shall promptly pay all Royalties required by this Sublicense Agreement. 

  

	 	(e)	ACENTIA shall maintain insurance pursuant to Article 7 and shall cause such insurance to name REVIMMUNE as a coinsured. 

 ARTICLE 3 - LICENSE GRANT 
 3.1 Grant of
License. 
 (a) Subject to the terms and conditions of this Agreement, REVIMMUNE hereby grants to ACCENTIA an exclusive (including to the
exclusion of REVIMMUNE), perpetual sublicense to the Sublicensed Rights throughout the Territory, with the right to grant further sublicenses, to develop, promote, market, sell, make, have made, use, import, offer for sale, and commercialize the
Sublicensed Products for the Sublicense Indications in the Territory. For clarification, ACCENTIA shall have no rights under this Agreement to develop, promote, market, sell, make, have made, use, import, offer for sale or commercialize any product
based on or using the Sublicensed Rights for the treatment of any disease, or for use in connection with, any indication other than the Sublicense Indications. The license grants in this paragraph shall apply to ACCENTIA and any of its Affiliates,
and if any Affiliate of ACCENTIA exercises rights under this Agreement, such Affiliate shall be bound by all the terms and payments, which shall apply to the exercise of the rights, to the same extent as would apply had this Agreement been directly
entered into between REVIMMUNE and such Affiliate. 
 3.2 Right to Grant Sublicenses. 
  

	 	(a)	 ACCENTIA shall have the right to sublicense the Sublicensed Rights in the Territory with the prior written approval of REVIMMUNE, which approval may not be
unreasonably withheld, provided: (i) the sublicensee agrees to be bound by all terms and conditions of this Sublicense Agreement as amended, including, but not limited to, the payment of all royalties to REVIMMUNE as provided in Article 4 as
though ACCENTIA itself had sold the Licensed Product (ii) ACCENTIA guarantees the performance of all material provisions of this Sublicense Agreement by its sublicensee; (iii) at the time of the sublicense, ACCENTIA is not in breach or
non-compliance with any material provision of this Sublicense Agreement, (iv) JHU consents in writing to the sublicense when required by the JHU License; (v) the sublicensee, in REVIMMUNE’s reasonable judgment, is reasonably capable
of developing, promoting, marketing, selling and commercializing the Sublicensed Products; (vi) the sublicensee, in REVIMMUNE’s reasonable judgment, is not a competitor of the Revimmune Licensed Rights; (vii) upon termination of this
Sublicense Agreement for any reason, the sublicense granted by ACCENTIA shall revert directly to REVIMMUNE, which may at its election recognize or disaffirm such sublicense and (viii) all fees in connection with or resulting from the sublicense
required by the JHU License and by this Sublicense Agreement are paid by Accentia. Each sublicense granted by ACCENTIA 



  

 4 









	 	 
pursuant to this Agreement shall be consistent the provisions of this Agreement and the JHU License. Prior to the grant of each sublicense hereunder,
ACCENTIA shall provide REVIMMUNE a copy of the sublicense. ACCENTIA shall not grant any paid-up license or accept equity in consideration, directly or indirectly, for such sublicenses without REVIMMUNE’s written approval.



  

	3.3	Intellectual Property. Title to any and all New Intellectual Property developed solely through the efforts of the employees, agents, independent contractors, or joint venture
partners of one Party shall vest solely and exclusively in such Party, provided that any such New Intellectual Property owned by REVIMMUNE will become subject to the licenses granted in this Agreement. Any New Intellectual Property developed through
the joint efforts of the employees, agents, independent contractors, or joint venture partners of both Parties shall be owned jointly by the Parties, provided that any such jointly owned New Intellectual Property shall be subject to the licenses
granted in this Agreement. “New Intellectual Property” shall mean any and all inventions, know-how, developments, methods, processes, improvements, and other information relating to the Revimmune Licensed Rights, Sublicensed Rights, or
Sublicensed Products in any form, technical or economic, patentable or unpatentable, confidential or otherwise to the extent they are first conceived or developed by either Party or by both Parties after the date of this Agreement.


  

	3.4	Rights of REVIMMUNE. REVIMMUNE shall, during the term of this Sublicense Agreement, have the absolute right, without notice to or consent from ACCENTIA or its sublicensees,
to: (i) sublicense, assign, develop, promote, sell, market, commercialize or otherwise deal with the Licensed Rights for any or all indications or diseases other than the Sublicense Indications and (ii) enter into any amendment,
modification or restatement of the License Agreement between REVIMMUNE and JHU including an amendment or modification to the Revimmune License Rights, provided that none of the actions in foregoing clauses (i) or (ii) shall narrow the
definitions of “Sublicensed Products” or “Territory” or increase the royalties, expenses, amounts payable, or other material obligations of ACCENTIA hereunder or under the JHU License without ACCENTIA’s prior written
consent. 

 ARTICLE 4 - ROYALTY AND OTHER PAYMENTS AND REPORTS 
 4.1 Relationship to JHU License. The Parties agree and acknowledge that ACCENTIA is an “Affiliated Party” of REVIMMUNE for purposes of the JHU License,
and accordingly, pursuant to Section 2.1 of the JHU License, ACCENTIA will be subject to the terms and royalty obligations of REVIMMUNE under the JHU License with respect to (and limited only to) the Sublicensed Products to the extent as would
apply if the JHU License were directly between JHU and ACCENTIA. Therefore, ACCENTIA agrees to make directly to JHU (and not to or through REVIMMUNE) any payments required under Article 3 of the JHU License with respect to (and limited only to) the
Sublicensed Products, subject to the following: 
 (a) ACCENTIA will not be required to pay the license fee required by Section 3.1 of
the JHU License, and REVIMMUNE represents and warrants that such fee has already been paid in full by REVIMMUNE. 
  

 5 








 (b) ACCENTIA will be required to pay the entire minimum annual royalty in Section 3.2 of the JHU
License until either REVIMMUNE or any third party licensee (including another Affiliated Company of REVIMMUNE) is granted license or sublicense rights under the JHU License or otherwise commences any development or commercialization efforts with
respect to Developed Products, Licensed Products, or Licensed Services (as those terms are defined in the JHU License), after which ACCENTIA will be responsible for paying only one-half (1/2) of such minimum annual royalties that become due
thereafter. 
 (c) ACCENTIA will be required to pay the milestone payments in Section 3.5 of the JHU License only if (i) with
respect to the milestone payment trigged by the issuance of patents, the Patent Claims in such patents relate directly and primarily to Sublicensed Products, or (ii) with respect to the milestone payment triggered by the regulatory approval of
a product, the approved product is a Sublicensed Product. REVIMMUNE will remain responsible for any and all other milestone payments. 
 (d)
ACCENTIA’s obligation to pay patent prosecution costs under Section 3.6 of the JHU License shall be limited to costs that actually and directly relate patents that are pending as of the date of this Agreement and that relate directly and
primarily to the Sublicensed Products, and REVIMMUNE will remain responsible for all other amounts required to be paid under said Section 3.6. 
 4.2
Initial License Fee. In addition to the amounts payable to JHU pursuant to Section 4.1 above, as consideration for entering into this Agreement, ACCENTIA shall pay to REVIMMUNE a one-time initial license fee of ten (10) dollars
within thirty (30) days of the Effective Date. 
 4.3 Sublicense Royalties. As consideration for the license rights granted ACCENTIA under this
Agreement and in addition to the amounts payable to JHU pursuant to Section 4.1 above, ACCENTIA will pay REVIMMUNE a running sublicense royalty that is calculated in the same manner as, and paid at the same time as, the running royalty that
ACCENTIA will be required to pay to JHU pursuant to Section 3.3 of the JHU License as a result of the sale of Sublicensed Products, except that the rate of such running sublicense royalty shall be four percent (4%) rather than the rate
indicated in paragraph 3 of the JHU License. 
 4.4 Sublicense Fee. Upon a sublicense by ACCENTIA of any Sublicensed Rights under this Agreement,
ACCENTIA shall pay to REVIMMUNE an amount equal to ten percent (10%) of the consideration received by ACCENTIA for the sublicense (other than sublicenses to Affiliates of ACCENTIA). This sublicense fee is in addition to the sublicense fee
required to be paid to JHU under the JHU License. This fee shall be payable on the same date as the corresponding sublicense fee is due and payable to JHU. 
 4.5 Fee at Product Approval. Upon the approval of each Sublicensed Product for sale or use in the U.S., ACCENTIA shall issue to REVIMMUNE a vested warrant to purchase 800,000 shares of ACCENTIA common stock at an exercise price equal
to the average of the volume weighted average closing prices of the ACCENTIA common stock during the ten (10) trading days immediately prior to the grant of such warrant; provided, however, that in the case of the warrant granted for the
approved of the first Sublicensed Warrant, the exercise price shall be $8 per share, subject to customary adjustment in the event of a stock dividend, stock split or other similar event. Each warrant granted under this Section 4.4 shall have a
term of three years. 
  

 6 








 4.6 Reports. ACCENTIA will provide to REVIMMUNE any and all reports that ACCENTIA provides to JHU pursuant to
Section 5.1 of the JHU License simultaneous to providing such reports to JHU. 
 4.7 Place of Payment. All payments due shall be payable in
United States dollars by wire transfer to a bank account designated by each Party from time to time. 
 4.8 Taxation of Payments. 
 (a) Insofar as any payment that is due under this Agreement is subject to any tax, duty, levy, or other government imposition, the Party receiving the
payment agrees to bear any and all such taxes, duties, levies or impositions. Each Party hereby authorizes the other Party to withhold such taxes, duties, levies or impositions from the payments in accordance with this Agreement if ACCENTIA or
REVIMMUNE is required to do so under the laws of the United States. Whenever a Party deducts such tax, duty, levy or imposition from any payments due, then it shall furnish the other Party with a certificate showing the payment of thereof to the
United States. 
 (b) In the event any payments which are due to under this Agreement are subject to value added taxation by any government,
then the Party receiving the payment shall bear such value added tax in full and the Party making the payment shall be reimbursed therefore. If appropriate, the Party receiving payment may add such value added taxes to its royalty accounts, provided
such value added taxes are credited against the other Party’s value added tax debt and the other Party is reimbursed in full with respect thereto. Notwithstanding anything herein to the contrary, the Party making the payment shall have no
liability for any value added tax directly or indirectly relating to thereto. 
 (c) In the event any payment is subject to a withholding or
other income tax in the Territory, promptly following becoming aware of the applicability of any such tax, the Party making the payment shall so advise the other Party. The Party receiving the payment shall have the right to contest with the
appropriate governmental body any such proposed withholding and the other Party shall provide, at receiving Party’s expense, reasonable cooperation in any such contest. The Parties shall provide each other with such receipts or other evidence
of any tax withheld as is necessary to claim any credit or deduction available to it in other jurisdictions. Payments shall only be reduced for withholding taxes imposed by the jurisdiction out of which the payment is directly made. 
 4.9 Interest. All payments due hereunder that are not paid when due and payable as specified in this agreement shall bear interest at an annual rate equal to the
prime rate (“Prime Rate”) for U.S. dollar deposits in effect from time to time, as published daily in the Wall Street Journal plus 2%, compounded monthly from the date due until paid, or at such lower rate of interest as shall then be the
maximum rate permitted by applicable law. 
 4.10 Right to Documentation. Upon request, REVIMMUNE shall have the right to request reasonable
documentation of ACCENTIA’s sublicensed royalty calculations to confirm the accuracy thereof and to request discussion of such calculations with appropriate representatives of ACCENTIA. 
 4.11 Records Retention. ACCENTIA shall keep complete and accurate records pertaining to the sale of Sublicensed Products in the Territory and covering all
transactions from which running sublicense royalties are derived for a period of three (3) calendar years after the year in which such sales occurred, 

  

 7 








 
and in sufficient detail to permit REVIMMUNE to confirm the accuracy of royalty calculations hereunder. Such records shall be available at all reasonable
times for inspection by REVIMMUNE or its representatives for verification of royalty payments or compliance with other aspects of this Agreement. 
 4.12
Audit Request. At the request of REVIMMUNE, ACCENTIA, its Affiliates and sublicensees shall permit an independent, certified public accountant appointed by REVIMMUNE acceptable to ACCENTIA, at reasonable times and upon reasonable notice, to
examine those records and all other material documents relating to or relevant to sales of Sublicensed Products in the possession or control of ACCENTIA or its sublicensees, for a period of three (3) years after the applicable sublicense
royalties have accrued, as may be necessary to: (i) determine the correctness of any report or payment made under this Agreement; or (ii) obtain information as to sublicense royalties payable for any calendar quarter in the case of
ACCENTIA’s or sublicensee’s failure to report or pay pursuant to this Agreement. Said accountant shall not disclose to REVIMMUNE any information other than information relating to said reports, royalties, and payments. Results of any such
examination shall be made available to both Parties. REVIMMUNE shall bear the full cost of the performance of any such audit, unless such audit demonstrates underpayment of sublicense royalties by ACCENTIA of more than ten percent (10%) from
the amount of the original sublicense royalty payment made by ACCENTIA. In such event, ACCENTIA shall bear the full cost of the performance of such audit. 
 4.13 Compliance by REVIMMUNE. REVIMMUNE hereby represents and warrants to ACCENTIA that REVIMMUNE has paid to JHU all fees and other amounts required to be paid to JHU under the JHU License through the date of this Agreement and that
REVIMMUNE is in full compliance with the JHU License Agreement, and has not breached the same, as of the date of this Agreement. 
 ARTICLE
5 - PATENT PROSECUTION; ENFORCEMENT; INFRINGEMENT 
 5.1 Patent Prosecution and Maintenance. 
 (a) Responsibility. The Parties hereby covenant, acknowledge and agree that the rights and responsibilities to prosecute and maintain any Patents
licensed to REVIMMUNE pursuant to the JHU License shall be governed by the terms of the JHU License. Accentia hereby assumes the cost and responsibility for patent prosecution of the licensed claims included in the Sublicensed Rights on the date
hereof to the extent that they actually and directly relate to Sublicensed Products. 
 (b) Cooperation. Each Party agrees to
cooperate with the other Party to execute any documents necessary or desirable to secure and perfect the other Party’s legal rights and worldwide ownership in the other Party’s intellectual property, including, but not limited to documents
relating to patent, trademark and copyright applications. Each Party agrees to take actions reasonably necessary to diligently prosecute and maintain its intellectual property in major commercial markets where viable protection is available. Each
party or its representatives shall be entitled to meet and confer with the other Party and their patent counsel at reasonable times and places. 
 5.2
Limitations on Publications. The Parties agree that no one Party shall publish the results of any studies, whether conducted by its own employees or in conjunction with a third party, carried out pursuant to this Agreement or
confidential information received from the other Party that is relating to a Sublicensed Product, without the prior written approval of the other Party. Each Party agrees to provide 

  

 8 








 
the other Party with a copy of any proposed abstracts, presentations, manuscripts, or any other disclosure which discloses clinical study results pursuant to
this Agreement or confidential information received from the other Party at least sixty (60) days prior to their intended submission for publication and agrees not to submit or present such disclosure until the Party not seeking to disclose
such information provides its prior written approval. Such written approval will not be unreasonably withheld unless such proposed disclosure could reasonably harm or impair a Party’s intellectual property assets or may reasonably cause
commercial harm to a Party. 
 5.3 Notification of Infringement. If either Party learns of an infringement or threatened infringement by a third party
of any Sublicensed Rights granted hereunder within the Territory, such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such infringement. Section 5.4 shall then be applicable.

 5.4 Patent Enforcement. REVIMMUNE shall have the first right, but not the duty, to institute patent infringement actions against third parties
based on any Sublicensed Rights under this Agreement. If REVIMMUNE does not institute an infringement proceeding against an offending third party within ninety (90) days after receipt of notice from ACCENTIA, ACCENTIA shall have the right, but
not the duty, to institute such an action. The costs and expenses of any such action (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and
maintaining such action, such costs and expenses shall be borne by the Parties in such proportions as they may agree in writing. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the
other Party to institute and prosecute such infringement actions. Any award paid by third parties as a result of such an infringement action (whether by way of settlement or otherwise) shall be paid to the Party who instituted and maintained such
action, or, if both Parties instituted and maintained such action, such award shall be allocated among the Parties in proportion to their respective contributions to the costs and expenses incurred in such action. 
 5.5 Infringement Action by Third Parties. 
 (a)
Claim or Suit Against ACCENTIA. In the event of the institution of any claim or suit by a third party against ACCENTIA for patent infringement involving the manufacture, use, or sale of any Sublicensed Product in the Territory, ACCENTIA shall
promptly notify REVIMMUNE in writing of such claim or suit, and REVIMMUNE will give ACCENTIA the full benefit of all of REVIMMUNE’s rights with respect thereto (including any rights under the JHU License). ACCENTIA shall have the right to
defend such claim or suit at its own expense and REVIMMUNE hereby agrees to assist and cooperate with ACCENTIA, at REVIMMUNE’s own expense, to the extent necessary in the defense of such claim or suit. During the pendency of such claim or suit,
ACCENTIA shall continue to make all payments due under this Agreement, but shall have a credit against Sublicensed Royalty payments otherwise payable hereunder for the full amount of all reasonable costs and expenses incurred by ACCENTIA in
defending against such claim or suit; provided, however, that in applying the credit against any royalty payments, the amount of such payment shall not be reduced by more than 50% and any remaining credit shall be applied against subsequent royalty
payments. 
 (b) Claim or Suit Against REVIMMUNE. In the event of the institution of any claim or suit by a third party against
REVIMMUNE for patent infringement involving the manufacture, use, or sale of any Sublicensed Product in the Territory covered by this Sublicense Agreement, REVIMMUNE shall 

  

 9 








 
promptly notify ACCENTIA in writing of such claim or suit. REVIMMUNE shall have the right but not the obligation to defend such claim or suit at its own
expense and ACCENTIA hereby agrees to assist and cooperate with REVIMMUNE, at ACCENTIA’s own expense (provided that Revimmune shall reimburse ACCENTIA for its out-of-pocket expenses), to the extent necessary in the defense of such claim or
suit. 
 ARTICLE 6 - CONFIDENTIALITY 
 6.1
Use of Name. REVIMMUNE agrees not to use directly or indirectly ACCENTIA’s name without ACCENTIA’s prior written consent. ACCENTIA agrees not to use directly or indirectly REVIMMUNE’s name or information without
REVIMMUNE’s prior written consent. Notwithstanding the foregoing, ACCENTIA and REVIMMUNE may include an accurate description of the terms of this Agreement to the extent required under federal or state securities laws or other disclosure; and
ACCENTIA may use REVIMMUNE’s names in various documents used by ACCENTIA for capital raising and financing purposes. 
 6.2 Confidentiality;
Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this Agreement and for the longer of three (3) years thereafter or the termination of the JHU
License, the receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose other than proper performance hereunder any information furnished to it by the other Party pursuant to this
Agreement, except to the extent that it can be established by the receiving Party by competent proof that such information: 
 (a) was
already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third party who had no obligation to the disclosing
Party not to disclose such information to others; or 
 (e) was independently developed by or for the receiving Party by persons not having
access to such information, as determined by the written records of such party. 
 6.3. Obligations of Employees and Consultants. The Parties each
represent that all of its employees and the employees of its Affiliates, and any collaborators or consultants to such Party or its Affiliates, who shall have access to confidential information of the Parties are bound by written obligations to
maintain such information in confidence and not to use such information except as expressly permitted herein. Each Party agrees to enforce confidentiality obligations to which its employees and consultants (and those of its Affiliates) are
obligated. 
  

 10 








 ARTICLE 7 - INDEMNIFICATION 
 7.1 Indemnification by ACCENTIA. ACCENTIA shall defend, indemnify and hold REVIMMUNE and JHU, their respective officers, directors, employees and consultants harmless from and against any and all third party
claims, suits or demands, threatened or filed, (“Claims”) for liability, damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals), at both trial and appellate levels, relating to the
distribution, testing, manufacture, use, sale, consumption on or application of Sublicensed Products by ACCENTIA, its Affiliates or its sublicensees pursuant to this Sublicense Agreement, including, without limitation, claims for any loss, damage,
or injury to persons or property, or loss of life, relating to the promotion and advertising of Sublicensed Products and/or interactions and communications with governmental authorities, physicians or other third parties relating to the Sublicensed
Products. The foregoing indemnification shall not apply to any third party Claims to the extent are caused by the gross negligence of REVIMMUNE or, in the case of indemnification of JHU by JHU, and the foregoing indemnification shall also not apply
to any Claims that would give rise to a REVIMMUNE indemnification obligations pursuant to Section 7.1 below or pursuant to any other provision of this Agreement. 
 7.2 Indemnification by REVIMMUNE. REVIMMUNE shall defend, indemnify and hold ACCENTIA, its officers, directors, employees and consultants harmless from and against any and all third party Claims for liability,
damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals), at both trial and appellate levels, relating to REVIMMUNE’s activities contemplated under this Agreement, including, but not limited
to, (a) breach of the representations, warranties and obligations of REVIMMUNE hereunder, or (b) any tax, duty, levy or government imposition on any sums payable by ACCENTIA to REVIMMUNE hereunder. The foregoing indemnification shall not
apply to any Claims to the extent caused by the gross negligence of ACCENTIA. 
 7.3 Notice. In the event that either Party seeks indemnification
under Sections 7.1 or 7.2, the Party seeking indemnification agrees to (i) promptly inform the other Party of the Third party Claim, (ii) permit the other Party to assume direction and control of the defense or claims resulting therefrom
(including the right to settle it at the sole discretion of that Party), and (iii) cooperate as reasonably requested (at the expense of that Party) in the defense of the Claim. 
 7.4 Insurance. 
 (a) Prior to the use of any Sublicensed Product in connection with a clinical trial
or the first sale of a Sublicensed Product which ever occurs first, ACCENTIA shall obtain and maintain broad form comprehensive general liability insurance and products liability insurance with a reputable and financially secure insurance carrier,
subject to approval by REVIMMUNE’s primary insurance broker, to cover such activities of ACCENTIA and ACCENTIA’s contractual indemnity under this Agreement. Such insurance shall provide minimum annual limits of liability of $3,000,000 per
occurrence and $5,000,000 in the aggregate with respect to all occurrences being indemnified under this Agreement. Such insurance policy shall name REVIMMUNE as an additional insured and shall be purchased and kept in force for the period of five
(5) years after the cessation of sales of all Sublicensed Products under this Agreement. 
  

 11 








 ARTICLE 8 – TERM; TERMINATION 
 8.1 Term. Unless earlier terminated under Section 8.2 hereof, this Agreement and the Sublicense granted hereby shall commence as of the Effective Date and, unless sooner terminated as provided hereunder,
shall have an initial term (the “Initial Term”) that shall terminate on the last to occur of: (i) Ten (10) years from the date hereof, (ii) the termination of the JHU License, or (iii) the expiration of the
last-to-expire of the patent claims included in the Sublicensed Rights. The Term shall be automatically extended by successive extension terms (the “Extension Terms”) of one (1) year each unless either party gives written notice of
its election not to extend the term at least ninety (90) days prior to the expiration of the Initial Term or of any Extension Term. Notwithstanding anything in this Agreement to the contrary, ACCENTIA may terminate this Agreement at any time
upon no less than sixty (60) days prior written notice. 
 8.2 Breach. Failure by either Party to comply with any of the material obligations
contained in this Agreement shall entitle the other Party to give to the Party in default notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within one hundred twenty (120) days after
the receipt of such notice (or, if such default cannot be cured within such 120 day period, if the Party in default does not commence and diligently continue actions to cure such default), the notifying Party shall be entitled, without prejudice to
any of its other rights conferred on it by this Agreement, in addition to any other remedies available to it by law or in equity, to terminate this Agreement by giving written notice to take effect within thirty (30) days after such notice
unless the defaulting Party shall cure such default within said thirty (30) days. The right of either Party to terminate this Agreement, as hereinabove provided, shall not be affected in any way by its waiver or failure to take action with
respect to any previous default. 
 8.3 Termination of Sublicenses. Upon any termination of this Agreement, all sublicenses granted by ACCENTIA under
this Agreement shall terminate simultaneously, subject, nevertheless, to Section 8.4. 
 8.4 Effect of Termination. Upon the termination of this
Sublicense Agreement, ACCENTIA and its sublicensees shall promptly: (i) return to REVIMMUNE all relevant records, materials or confidential information of REVIMMUNE concerning the REVIMMUNE Licensed Rights relating to such Sublicensed Product
in the possession or control of ACCENTIA or its sublicensees; (ii) assign to REVIMMUNE, or REVIMMUNE’s designee, its registrations with governmental health authorities, licensees, and approvals of such Sublicensed Product in the Territory
and (iii) cease and desist from developing, promoting, marketing, selling or commercializing any Sublicensed Product (except to the extent reasonably necessary to liquidate existing inventories and fulfill then-existing orders and obligations).

 8.5 Surviving Rights. Termination of this Agreement shall not terminate ACCENTIA’s obligation to comply with Articles 4, 5, 6 and 7 hereunder,
provided that from and after such termination, ACCENTIA shall have no further monetary obligations other than monetary obligations that have accrued through the effective date of termination. For purposes of clarification and not of limitation, upon
any termination of this Agreement, ACCENTIA shall have no further obligation to pay patent prosecution costs pursuant to Section 3.6 of the JHU License or Section 4.1(d) of this Agreement. 
  

 12 








 8.6 Accrued Rights, Surviving Obligations. Termination, relinquishment or expiration of this Agreement for any
reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party under this Agreement prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve
either Party from obligations which are expressly indicated to survive termination or expiration of this Agreement. 
 ARTICLE 9 -
MISCELLANEOUS PROVISIONS 
 10.1 Relationship of Parties. Nothing in this Agreement is or shall be deemed to constitute a partnership, agency,
employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 
 10.2 Inter-relationships. REVIMMUNE and ACCENTIA each acknowledge that a Hopkins Capital Group, LLC entity owns an equity interest in both REVIMMUNE and ACCENTIA
and that Frank O’Donnell, MD is an affiliate and founder of the Hopkins Capital Group, LLC entities, REVIMMUNE and ACCENTIA. ACCENTIA represents that its Audit Committee and independent directors have been fully advised of these
inter-relationships. 
 10.3 Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable by
ACCENTIA without the prior written consent of REVIMMUNE; provided, however, that either Party may assign this Agreement to any wholly-owned subsidiary or to any successor by merger or sale of substantially all of its assets to which this Sublicense
Agreement relates in a manner such that the assignor shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder. This Sublicense Agreement shall be binding upon the successors and permitted
assigns of the parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in
accordance with this Section 10.3 shall be void. 
 10.4 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.5
Force Majeure. Neither Party shall be liable to the other for loss or damages nor shall have any right to terminate this Agreement for any default or delay attributable to any act of God, flood, fire, explosion, strike, lockout, labor
dispute, shortage of raw materials, casualty, accident, war, revolution, civil commotion, act of public enemies, blockage or embargo, injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or
subdivision, authority or representative of any such government, or any other cause beyond the reasonable control of such Party, if the Party affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall
thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty (30) days thereafter. Notwithstanding the foregoing, nothing in this Section 10.5 shall
excuse or suspend the obligation to make any payment due hereunder in the manner and at the time provided. 
  

 13 








 10.6 No Trademark Rights. Except as otherwise provided herein, no right, express or implied, is granted by this
Agreement to use in any manner the name “ACCENTIA” or “REVIMMUNE” or any other trade name or trademark of the other party in connection with the performance of this Agreement. 
 10.7 Public Announcements. Except as required by law, neither Party shall make any public announcement concerning this Agreement or the subject matter hereof
without the prior written consent of the other. In the event of a legally-required public announcement, the Party making such announcement shall provide the other with a copy of the proposed text prior to such announcement. 
 10.8 Notices. Any notice required or permitted to be given or delivered hereunder or by reason of the provisions of this Agreement shall be in writing and shall
be deemed to have been properly served if: (a) delivered personally, (b) delivered by a recognized overnight courier service instructed to provide next-day delivery, (c) sent by certified or registered mail, return receipt requested
and first class postage prepaid, or (d) sent by facsimile transmission followed by confirmation copy delivered by a recognized overnight courier service the next day. Such notices, demands and other communications shall be sent to the addresses
set forth below, or to such other addresses or to the attention of such other person as the recipient Party has specified by prior written notice to the sending Party. Date of service of such notice shall be: (i) the date such notice is
personally delivered or sent by facsimile transmission (with issuance by the transmitting machine of confirmation of successful transmission), (ii) three days after the date of mailing if sent by certified or registered mail, or (iii) one
day after date of delivery to the overnight courier if sent by overnight courier. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below: 
 (a) If to REVIMMUNE, addressed to: 
 Revimmune, LLC 
 Suite 350 
 324 S. Hyde Park Ave. 
 Tampa, FL 33606 
 Attn: CEO 
 (b) If to ACCENTIA, addressed to: 
 ACCENTIA Biopharmaceuticals, Inc. 
 Suite 350 
 324 S. Hyde Park Ave. 
 Tampa, FL 33606 
 Attn: CEO 
 10.9 Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a
duly authorized officer of each Party. This Agreement may be executed in a series of counterparts, all of which, when taken together, shall constitute one and the same instrument. 
  

 14 








 10.10 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its
agents or employees except by an instrument in writing expressly waiving such provision and signed by the waiving Party. 
 10.11 Dispute Resolution.

 (a) Senior Officials. The Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the
term of this Agreement which relates to either Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by notice to the other Party, have such dispute referred to their respective senior
officials designated below or their successors, for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. Said designated senior officials are as follows: 
  

			
	For ACCENTIA:	  	Chairman of the Audit Committee
		
	For REVIMMUNE:	  	Frank O’Donnell, M.D. Managing Member

 In the event the designated senior officials are not able to resolve such dispute within the thirty (30) day
period, either Party may invoke the provisions of Section 10.11(b). 
 (b) Arbitration. In the event of any dispute, difference
or question arising between the Parties in connection with this Agreement, the construction thereof, or the rights, duties or liabilities of either Party, and which dispute cannot be amicably resolved by the good faith efforts of both Parties, then
such dispute shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration panel shall be composed of three arbitrators, one of whom shall be chosen by
REVIMMUNE, one by ACCENTIA, and the third by the two so chosen. If both or either of ACCENTIA or REVIMMUNE fails to choose an arbitrator or arbitrators within fourteen (14) days after receiving notice of commencement of arbitration or if the
two arbitrators fail to choose a third arbitrator within fourteen (14) days after their appointment, the then President of the American Arbitration Association shall, upon the request of both or either of the Parties to the arbitration, appoint
the arbitrator or arbitrators required to complete the board or, if he shall decline or fail to do so, such arbitrator or arbitrators shall be appointed by the American Arbitration Association. The decision of the arbitrators shall be by majority
vote and, at the request of either Party, the arbitrators shall issue a written opinion of findings of fact and conclusions of law. Costs shall be borne as determined by the arbitrators. Unless the Parties to the arbitration shall otherwise agree to
a place of arbitration, the place of arbitration shall be at Tampa, Florida, U.S.A. The arbitration award shall be final and binding upon the Parties to such arbitration and may be entered in any court having jurisdiction. 
 10.12 Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of FLORIDA. 
 10.13 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but
if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

  

 15 








 10.14 Entire Agreement of the Parties. This Agreement constitutes and contains the entire understanding and
agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. 
 [NEXT PAGE IS THE SIGNATURE PAGE] 
  

 16 








 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized
officer as of the day and year first above written. 
  

			
	 REVIMMUNE LLC

		
	 By:
	 	 /s/ Francis E. O’Donnell, Jr.

	 Name:
	 	 Francis E. O’Donnell, Jr., M.D.

	 Title:
	 	 Managing Member

	
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ James A. McNulty

	 Name:
	 	 James A. McNulty, CPA

	 Title:
	 	 Secretary/Treasurer



  

 17